The original success of Sildenafil undeniably transformed the pharmaceutical landscape, but betting in companies heavily reliant on off-patent versions presents a uncertain picture. Despite early returns were impressive, the end of patents and the emergence of less expensive alternatives have diminished the customer base. Thus, a thorough analysis